Session Information
-
WCLC 2022
2022 World Conference on Lung Cancer
Conference Program for 2022 the World Conference on Lung Cancer
Presentation Date(s):- August 6 - 9, 2022
- Total Presentations: 2137
All times listed are in Vienna, Austria Time, CEST (UTC+2:00)
PL - Plenary
IBS - Interactive Breakfast Session (in-person attendees only)
ES - Education Session
OA - Oral Session
MA - Mini Oral Session
P - Posters
EP - ePosters
WS - Workshops
LA – Lectureship Awards
IS - Industry Symposium
August 5 Fri
Aug 5 Saturday
August 6 Sat
Aug 6 Sunday
August 7 Sun
Aug 7 Monday
August 8 Mon
Aug 8 Tuesday
August 9 Tue
Aug 9
-
+
WS08 - Joint IASLC-CSCO-CAALC Session: Liquid Biopsy in Oncogene Driven NSCLC (On-demand)
- 21:00 - 23:59
- 8/06/2022
- Location: On-Demand
- Not for CME Credit
- Type: Workshop
- Track: N/A
- Moderators:Yi-Long Wu, Chunxue Bai, Caicun Zhou, Karen Kelly
-
+
Session Moderator
21:00 - 21:00 | Presenter: Yi-Long Wu
- Abstract
Loading... -
+
Session Moderator
21:00 - 21:00 | Presenter: Chunxue Bai
- Abstract
Loading... -
+
Session Moderator
21:00 - 21:00 | Presenter: Caicun Zhou
- Abstract
Loading... -
+
Session Moderator
21:00 - 21:00 | Presenter: Karen Kelly
- Abstract
Loading... -
+
WS08.01 - Session Introduction
21:00 - 21:02 | Presenter: Yi-Long Wu
- Abstract
Loading... -
+
WS08.02 - Session Introduction
21:02 - 21:04 | Presenter: Chunxue Bai
- Abstract
Loading... -
+
WS08.03 - Session Introduction
21:04 - 21:07 | Presenter: Caicun Zhou
- Abstract
Loading... -
+
WS08.04 - Session Introduction
21:07 - 21:10 | Presenter: Karen Kelly
- Abstract
Loading... -
+
WS08.05 - Minimal Residual Disease (MRD) Negative: Potential for Cure in Resected Oncogene Driven NSCLC? Chinese Perspective
21:10 - 21:30 | Presenter: Jia-Tao Zhang
- Abstract
Loading... -
+
WS08.06 - Could MRD Change Our Clinical Practice? North American Perspective
21:30 - 21:50 | Presenter: Aadel Chaudhuri
- Abstract
Loading... -
+
WS08.07 - How to Use Liquid Biopsy to Monitor Treatment Efficacy for Advanced Driven NSCLC
21:50 - 22:10 | Presenter: Jie Hu
- Abstract
Loading... -
+
WS08.08 - Liquid Biopsy for Advanced Oncogene Driven NSCLC. European Perspective
22:10 - 22:30 | Presenter: Martin Filipits
- Abstract
Loading... -
+
WS08.09 - Sintilimab versus Pembrolizumab as Monotherapy or in Combination with Chemotherapy for Treatment Naïve Metastatic Non-small Cell Lung Cancer
22:30 - 22:40 | Presenter: Si-Yang Maggie Liu
- Abstract
Loading... -
+
WS08.10 - Toripalimab in Combination with CIK Cells in Patients with Advanced NSCLC: An Exploratory Study
22:40 - 22:50 | Presenter: Xuxinyi Ling
- Abstract
Loading... -
+
WS08.11 - Entrectinib in Patients with ROS1 Fusion-Positive (ROS1-fp) NSCLC: Updated Efficacy and Safety Analysis
22:50 - 23:00 | Presenter: Yun Fan
- Abstract
This abstract is currently under embargo and will be released during the conference.
-
+
WS08.12 - Discussant for Oral Abstracts
23:00 - 23:20 | Presenter: Sai-Hong Ignatius Ou
- Abstract
Loading... -
+
WS08.13 - Activity of aPD1-MSLN-CART Cells Against Metastatic Lung Cancer in a Phase 1 Trial
23:20 - 23:21 | Presenter: Xiaorong Dong
- Abstract
Loading... -
+
WS08.14 - Final Analyses of ALTER-L018: A Randomized Phase II Trial of Anlotinib Plus Docetaxel vs Docetaxel as 2nd-line Therapy for EGFR-Negative NSCLC
23:21 - 23:22 | Presenter: Lin Wu
- Abstract
Loading... -
+
WS08.15 - Safety and Efficacy of Sitravatinib + Tislelizumab in Patients with PD-L1+, Locally Advanced/Metastatic, Squamous NSCLC
23:22 - 23:23 | Presenter: Jun Zhao
- Abstract
Loading... -
+
WS08.16 - The Increase of Blood Intratumor Heterogeneity is Associated with Unfavorable Outcomes of ICIs Plus Chemotherapy in NSCLC
23:23 - 23:24 | Presenter: Juan Zhou
- Abstract
Loading... -
+
WS08.17 - Utilization of Tumor Mutational Profiling to Identify the Immunotherapy Response in Non-small Cell Lung Cancer
23:24 - 23:25 | Presenter: Wenbin Li
- Abstract
Loading... -
+
WS08.18 - Discussant for Poster 1 - 5
23:25 - 23:40 | Presenter: Xiaorong Dong
- Abstract
Loading... -
+
WS08.19 - Phase Il Trial of Neoadjuvant Tislelizumab with Chemotherapy for Resectable Stage IIB-III Non-small Cell Lung Cancer
23:40 - 23:41 | Presenter: Yao-Bin Lin
- Abstract
Loading... -
+
WS08.20 - Comprehensive Analysis of a Dendritic Cell Marker Genes Signature to Predict Prognosis and Immunotherapy Response in Lung Adenocarcinoma
23:41 - 23:42 | Presenter: Yuan Li
- Abstract
Loading... -
+
WS08.21 - Immune Evolution of Metastases & Underlying Molecular Mechanisms in Non-small Cell Lung Cancer
23:42 - 23:43 | Presenter: Wen-Fang Tang
- Abstract
Loading... -
+
WS08.22 - Neoadjuvant Toripalimab Combination in Patients with Stage IIB-IIIB NSCLC: A Single-arm, Phase 2 Trial (Renaissance Study)
23:43 - 23:44 | Presenter: Shi Yan
- Abstract
Loading... -
+
WS08.23 - Transcriptomic Heterogeneity in Non-Small Cell Lung Cancer with Four Structure-Based EGFR-Mutation Subgroups
23:44 - 23:45 | Presenter: Shun Lu
- Abstract
Loading... -
+
WS08.24 - Discussant for Poster 6 - 10
23:35 - 23:50 | Presenter: Ming Fang Zhao
- Abstract
Loading...
-
+
MA02 - Molecular Underpinnings of Lung Cancer Histological Differentiation and Targeted Therapeutics
- 10:45 - 11:45
- 8/07/2022
- Location: Hall C8
- Not for CME Credit
- Type: Mini Oral
- Track: Tumor Biology and Biomarkers
- Moderators:Erik Thunnissen, Rafael Rosell
-
+
MA02.05 - Dynamic Mutation Profiles of SCLC Transformation in NSCLC Patients Harboring Concurrent EGFR/TP53/RB1 Mutations
10:57 - 11:02 | Presenter: Jie Huang
- Abstract
Loading...
-
+
OA02 - From Locally Advanced to Unresectable NSCLC: Improvement of Multimodality Treatment
- 12:00 - 13:00
- 8/07/2022
- Location: Hall C7
- Not for CME Credit
- Type: Oral
- Track: Locally Advanced Non-small Cell Lung Cancer
- Moderators:Isabelle Opitz, Luis Paz-Ares
-
+
OA02.05 - Sugemalimab vs Placebo after cCRT or sCRT in pts with Unresectable Stage III NSCLC: Final PFS Analysis of a Phase 3 Study
12:22 - 12:32 | Presenter: Yi-Long Wu
- Abstract
Loading...
-
+
OA03 - Molecular Targeted Treatments
- 14:30 - 15:40
- 8/07/2022
- Location: Hall C7
- Not for CME Credit
- Type: Oral
- Track: Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments
- Moderators:Andrew Ciupek, David R. Gandara
-
+
OA03.05 - Tepotinib in Patients with MET Exon 14 (METex14) Skipping NSCLC: Primary Analysis of the Confirmatory VISION Cohort C
14:52 - 15:02 | Presenter: Michael Thomas
- Abstract
Loading...
-
+
EP08.01 - Metastatic Non-small Cell Lung Cancer - Immunotherapy
- 09:45 - 18:00
- 8/07/2022
- Location: Exhibit Hall - Hall B
- Not for CME Credit
- Type: E-Poster
- Track: Metastatic Non-small Cell Lung Cancer - Immunotherapy
-
+
EP08.01-070 - Safety and Efficacy of Sitravatinib + Tislelizumab in Patients with PD-L1+, Locally Advanced/Metastatic, Squamous NSCLC
Presenter: Jun Zhao- Abstract
Loading... -
+
EP08.01-071 - Safety and Efficacy of Sitravatinib + Tislelizumab in Patients with PD-L1+, Locally Advanced/Metastatic, Non-Squamous NSCLC
Presenter: Jun Zhao- Abstract
Loading... -
+
EP08.01-085 - Sintilimab versus Pembrolizumab as Monotherapy or in Combination with Chemotherapy for Treatment Naïve Metastatic Non-small Cell Lung Cancer
Presenter: Si-Yang Maggie Liu- Abstract
Loading...
-
+
EP08.02 - Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments
- 09:45 - 18:00
- 8/07/2022
- Location: Exhibit Hall - Hall B
- Not for CME Credit
- Type: E-Poster
- Track: Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments
-
+
EP08.02-049 - A Phase I Trial of the HER2 Exon 20 Inhibitor, BI 1810631, In Patients With Advanced Solid Tumors With HER2 Aberrations
Presenter: Frans Opdam- Abstract
Loading... -
+
EP08.02-063 - SANOVO: A Phase 3 Study of Savolitinib or Placebo in Combination with Osimertinib in Patients with EGFR-mutant and MET Overexpressed NSCLC
Presenter: Qing Zhou- Abstract
Loading... -
+
EP08.02-064 - ASTRIS China: A Real-world Study of Osimertinib in Patients with EGFR T790M Positive Non-small-cell Lung Cancer (NSCLC)
Presenter: Qing Zhou- Abstract
Loading... -
+
EP08.02-108 - Osimertinib Long-Term Tolerability in Patients with EGFRm NSCLC Enrolled in the AURA Program or FLAURA Study
Presenter: Marina Chiara Garassino- Abstract
Loading...
-
+
EP10.01 - Palliative and Supportive Care
- 09:45 - 18:00
- 8/07/2022
- Location: Exhibit Hall - Hall B
- Not for CME Credit
- Type: E-Poster
- Track: Palliative and Supportive Care
-
+
EP10.01-010 - Real-world Study of the Incidence and Risk Factors of Venous Thromboembolism in Chinese Lung Cancer (RIVAL)
Presenter: ZHEN WANG- Abstract
Loading...
-
+
EP16.01 - Tumor Biology and Biomarkers - Immune Biology & Immunotherapy
- 09:45 - 18:00
- 8/07/2022
- Location: Exhibit Hall - Hall B
- Not for CME Credit
- Type: E-Poster
- Track: Tumor Biology and Biomarkers - Immune Biology & Immunotherapy
-
+
EP16.01-025 - Immune Evolution of Metastases & Underlying Molecular Mechanisms in Non-small Cell Lung Cancer
Presenter: Wen-Fang Tang- Abstract
Loading...
-
+
EP16.02 - Tumor Biology and Biomarkers - Minimally Invasive Biomarkers
- 09:45 - 18:00
- 8/07/2022
- Location: Exhibit Hall - Hall B
- Not for CME Credit
- Type: E-Poster
- Track: Tumor Biology and Biomarkers - Minimally Invasive Biomarkers
-
+
EP16.02-024 - Plasma ctDNA Organ-Specific Genomic Patterns and Origination Analysis in Advanced Non-Small Cell Lung Cancer
Presenter: Rui Fu- Abstract
Loading...
-
+
OA15 - Patient Selection in Advanced NSCLC Immunotherapy
- 14:30 - 15:30
- 8/09/2022
- Location: Hall C7
- Not for CME Credit
- Type: Oral
- Track: Metastatic Non-small Cell Lung Cancer - Immunotherapy
- Moderators:Pilar Garrido, António Araújo
-
+
OA15.06 - Pooled Analysis of Outcomes With Second-Course Pembrolizumab Across 5 Phase 3 Studies of Non-Small-Cell Lung Cancer
15:02 - 15:12 | Presenter: Delvys Rodriguez-Abreu
- Abstract
Loading...